The DOI matches its Crossref record; 173 of the 173 references it cites were found in a registry or an index.
Therapeutic Strategies for Targeting Ras Proteins
Open accessAbstract
Ras genes are frequently activated in cancer. Attempts to develop drugs that target mutant Ras proteins have, so far, been unsuccessful. Tumors bearing these mutations, therefore, remain among the most difficult to treat. Most efforts to block activated Ras have focused on pathways downstream. Drugs that inhibit Raf kinase have shown clinical benefit in the treatment of malignant melanoma. However, these drugs have failed to show clinical benefit in Ras mutant tumors. It remains unclear to what extent Ras depends on Raf kinase for transforming activity, even though Raf proteins bind directly to Ras and are certainly major effectors of Ras action in normal cells and in development. Furthermore, Raf kinase inhibitors can lead to paradoxical activation of the MAPK pathway. MEK inhibitors block the Ras-MAPK pathway, but often activate the PI3'-kinase, and have shown little clinical benefit as single agents. This activation is mediated by EGF-R and other receptor tyrosine kinases through relief of a negative feedback loop from ERK. Drug combinations that target multiple points within the Ras signaling network are likely to be necessary to achieve substantial clinical benefit. Other effectors may also contribute to Ras signaling and provide a source of targets. In addition, unbiased screens for genes necessary for Ras transformation have revealed new potential targets and have added to our understanding of Ras cancer biology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,890
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
Maehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K. A., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., et al. (1997) · Nature Genetics · doi:10.1038/ng0497-356 · Cited by 2,741
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,192
The P-loop — a common motif in ATP- and GTP-binding proteins
Saraste, M., Sibbald, P. R., & Wittinghofer, A. (1990) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(90)90281-f · Cited by 2,056
Cowley, S. (1994) · Cell · doi:10.1016/0092-8674(94)90133-3 · Cited by 1,966
Phosphatidylinositol-3-OH kinase direct target of Ras
Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., & Downward, J. (1994) · Nature · doi:10.1038/370527a0 · Cited by 1,954
Mammalian Ras interacts directly with the serine/threonine kinase raf
Vojtek, A. B., Hollenberg, S. M., & Cooper, J. A. (1993) · Cell · doi:10.1016/0092-8674(93)90307-c · Cited by 1,941
The Guanine Nucleotide-Binding Switch in Three Dimensions
Vetter, I. R., & Wittinghofer, A. (2001) · Science · doi:10.1126/science.1062023 · Cited by 1,875
PI3K pathway alterations in cancer: variations on a theme
Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W., Zhang, C., Zhang, Y., Habets, G., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,831
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2130 · Cited by 1,829
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M., & Rosen, N. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,811
All ras proteins are polyisoprenylated but only some are palmitoylated
Hancock, J. F., Magee, A. I., Childs, J. E., & Marshall, C. J. (1989) · Cell · doi:10.1016/0092-8674(89)90054-8 · Cited by 1,799
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hatzivassiliou, G., Song, K., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,622
Hyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
The Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants
Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., & Wittinghofer, A. (1997) · Science · doi:10.1126/science.277.5324.333 · Cited by 1,543
Ras oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Heidorn, S. J., Milagre, C., Whittaker, S., Nourry, A., Niculescu-Duvas, I., Dhomen, N., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,465
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
BRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2006) · Nature · doi:10.1038/nature04304 · Cited by 1,328
Villanueva, J., Vultur, A., Lee, J. T., Somasundaram, R., Fukunaga-Kalabis, M., Cipolla, A. K., Wubbenhorst, B., Xu, X., Gimotty, P. A., Kee, D., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.023 · Cited by 1,259
The PI3K Pathway As Drug Target in Human Cancer
Courtney, K. D., Corcoran, R. B., & Engelman, J. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3641 · Cited by 1,237
RAF/RAS oncogenes and mismatch-repair status
Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Nature · doi:10.1038/418934a · Cited by 1,224
A Cytoplasmic Protein Stimulates Normal N- ras p21 GTPase, But Does Not Affect Oncogenic Mutants
Trahey, M., & McCormick, F. (1987) · Science · doi:10.1126/science.2821624 · Cited by 1,211
Self-citationPhase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Abou-Alfa, G. K., Schwartz, L., Ricci, S., Amadori, D., Santoro, A., Figer, A., De Greve, J., Douillard, J.-Y., Lathia, C., Schwartz, B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.3441 · Cited by 1,195
FUNCTION AND REGULATION OF RAS
Lowy, D. R., & Willumsen, B. M. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.62.070193.004223 · Cited by 1,186
Rodriguez-Viciana, P., Warne, P. H., Khwaja, A., Marte, B. M., Pappin, D., Das, P., Waterfield, M. D., Ridley, A., & Downward, J. (1997) · Cell · doi:10.1016/s0092-8674(00)80226-3 · Cited by 1,061
A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
Luo, J., Emanuele, M. J., Li, D., Creighton, C. J., Schlabach, M. R., Westbrook, T. F., Wong, K.-K., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.05.006 · Cited by 1,017
Complexes of Ras⋅GTP with Raf-1 and Mitogen-Activated Protein Kinase Kinase
Moodie, S. A., Willumsen, B. M., Weber, M. J., & Wolfman, A. (1993) · Science · doi:10.1126/science.8503013 · Cited by 968
An essential role for Rac in Ras transformation
Qiu, R.-G., Chen, J., Kirn, D., McCormick, F., & Symons, M. (1995) · Nature · doi:10.1038/374457a0 · Cited by 882
Self-citationNormal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1
Zhang, X.-F., Settleman, J., Kyriakis, J., Takeuchi-Suzuki, E., Elledge, S. J., Marshall, M. S., Bruder, J. T., Rapp, U. R., & Avruch, J. (1993) · Nature · doi:10.1038/364308a0 · Cited by 858
p21ras is modified by a farnesyl isoprenoid.
Casey, P. J., Solski, P. A., Der, C. J., & Buss, J. E. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.21.8323 · Cited by 856
Singh, A., Greninger, P., Rhodes, D., Koopman, L., Violette, S., Bardeesy, N., & Settleman, J. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.022 · Cited by 841
Molecular alterations of the AKT 2 oncogene in ovarian and breast carcinomas
Bellacosa, A., De Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640412 · Cited by 837
Modelling Myc inhibition as a cancer therapy
Soucek, L., Whitfield, J., Martins, C. P., Finch, A. J., Murphy, D. J., Sodir, N. M., Karnezis, A. N., Swigart, L. B., Nasi, S., & Evan, G. I. (2008) · Nature · doi:10.1038/nature07260 · Cited by 817
Inhibition of NIH 3T3 cell proliferation by a mutant ras protein with preferential affinity for GDP.
Feig, L. A., & Cooper, G. M. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.8.3235 · Cited by 798
Cheng, J. Q., Ruggeri, B., Klein, W. M., Sonoda, G., Altomare, D. A., Watson, D. K., & Testa, J. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3636 · Cited by 793
Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro
Warne, P. H., Vician, P. R., & Downward, J. (1993) · Nature · doi:10.1038/364352a0 · Cited by 712
Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation
Khosravi-Far, R., Solski, P. A., Clark, G. J., Kinch, M. S., & Der, C. J. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.11.6443 · Cited by 683
Multiple ras functions can contribute to mammalian cell transformation
White, M. A., Nicolette, C., Minden, A., Polverino, A., Aelst, L. V., Karin, M., & Wigler, M. H. (1995) · Cell · doi:10.1016/0092-8674(95)90507-3 · Cited by 649
Nassar, N., Horn, G., Herrmann, C. A., Scherer, A., McCormick, F., & Wittinghofer, A. (1995) · Nature · doi:10.1038/375554a0 · Cited by 635
Self-citationBenzodiazepine Peptidomimetics: Potent Inhibitors of Ras Farnesylation In Animal Cells
James, G. L., Goldstein, J. L., Brown, M. S., Rawson, T. E., Somers, T. C., McDowell, R. S., Crowley, C. W., Lucas, B. K., Levinson, A. D., & Marsters, J. C. (1993) · Science · doi:10.1126/science.8316834 · Cited by 630
Crystal Structure and Functional Analysis of Ras Binding to Its Effector Phosphoinositide 3-Kinase γ
Pacold, M. E., Suire, S., Perisic, O., Lara-Gonzalez, S., Davis, C. T., Walker, E. H., Hawkins, P. T., Stephens, L., Eccleston, J. F., & Williams, R. L. (2000) · Cell · doi:10.1016/s0092-8674(00)00196-3 · Cited by 602
Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome
Niihori, T., Aoki, Y., Narumi, Y., Neri, G., Cavé, H., Verloes, A., Okamoto, N., Hennekam, R. C. M., Gillessen-Kaesbach, G., Wieczorek, D., et al. (2006) · Nature Genetics · doi:10.1038/ng1749 · Cited by 599
Class I PI3K in oncogenic cellular transformation
Zhao, L., & Vogt, P. K. (2008) · Oncogene · doi:10.1038/onc.2008.244 · Cited by 594
Binding of Ras to Phosphoinositide 3-Kinase p110α Is Required for Ras- Driven Tumorigenesis in Mice
Gupta, S., Ramjaun, A. R., Haiko, P., Wang, Y., Warne, P. H., Nicke, B., Nye, E., Stamp, G., Alitalo, K., & Downward, J. (2007) · Cell · doi:10.1016/j.cell.2007.03.051 · Cited by 589
The p21 ras C-terminus is required for transformation and membrane association
Willumsen, B. M., Christensen, A., Hubbert, N. L., Papageorge, A. G., & Lowy, D. R. (1984) · Nature · doi:10.1038/310583a0 · Cited by 584
Germline Mutations in Genes Within the MAPK Pathway Cause Cardio-facio-cutaneous Syndrome
Rodriguez-Viciana, P., Tetsu, O., Tidyman, W. E., Estep, A. L., Conger, B. A., Cruz, M. S., McCormick, F., & Rauen, K. A. (2006) · Science · doi:10.1126/science.1124642 · Cited by 571
Self-citationTargeting the PI3K signaling pathway in cancer
Wong, K.-K., Engelman, J. A., & Cantley, L. C. (2010) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.11.002 · Cited by 543
Scholl, C., Fröhling, S., Dunn, I. F., Schinzel, A. C., Barbie, D. A., Kim, S. Y., Silver, S. J., Tamayo, P., Wadlow, R. C., Ramaswamy, S., et al. (2009) · Cell · doi:10.1016/j.cell.2009.03.017 · Cited by 538
Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma
Meylan, E., Dooley, A. L., Feldser, D. M., Shen, L., Turk, E., Ouyang, C., & Jacks, T. (2009) · Nature · doi:10.1038/nature08462 · Cited by 517
The RCSB PDB information portal for structural genomics
Kouranov, A. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj120 · Cited by 515
Structural insights into phosphoinositide 3-kinase catalysis and signalling
Walker, E. H., Perisic, O., Ried, C., Stephens, L., & Williams, R. L. (1999) · Nature · doi:10.1038/46319 · Cited by 494
Raf-1 protein kinase is required for growth of induced NIH/3T3 cells
Kolch, W., Heidecker, G., Lloyd, P., & Rapp, U. R. (1991) · Nature · doi:10.1038/349426a0 · Cited by 474
Genetic Interaction Between NRAS and BRAF Mutations and PTEN/MMAC1 Inactivation in Melanoma
Tsao, H., Yang, G., Goel, V., Wu, H., & Haluska, F. G. (2004) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2004.22243.x · Cited by 467
Hoeflich, K. P., O'Brien, C., Boyd, Z., Cavet, G., Guerrero, S., Jung, K., Januario, T., Savage, H., Punnoose, E., Truong, T., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0317 · Cited by 463
Mitchell, D. A., Vasudevan, A., Linder, M. E., & Deschenes, R. J. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r600007-jlr200 · Cited by 456
PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
Wee, S., Jagani, Z., Xiang, K. X., Loo, A., Dorsch, M., Yao, Y.-M., Sellers, W. R., Lengauer, C., & Stegmeier, F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4765 · Cited by 455
Distinct requirements for Ras oncogenesis in human versus mouse cells
Hamad, N. M., Elconin, J. H., Karnoub, A. E., Bai, W., Rich, J. N., Abraham, R. T., Der, C. J., & Counter, C. M. (2002) · Genes & Development · doi:10.1101/gad.993902 · Cited by 431
Requirement for CDK4 kinase function in breast cancer
Yu, Q., Sicinska, E., Geng, Y., Ahnström, M., Zagozdzon, A., Kong, Y., Gardner, H., Kiyokawa, H., Harris, L. N., Stål, O., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.012 · Cited by 429
Puyol, M., Martín, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G., Guerra, C., Santamaría, D., & Barbacid, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.025 · Cited by 415
Mirzoeva, O. K., Das, D., Heiser, L. M., Bhattacharya, S., Siwak, D., Gendelman, R., Bayani, N., Wang, N. J., Neve, R. M., Guan, Y., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3389 · Cited by 385
Self-citationMice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumours
Malliri, A., van der Kammen, R. A., Clark, K., van der Valk, M., Michiels, F., & Collard, J. G. (2002) · Nature · doi:10.1038/nature00848 · Cited by 384
The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders
Aoki, Y., Niihori, T., Narumi, Y., Kure, S., & Matsubara, Y. (2008) · Human Mutation · doi:10.1002/humu.20748 · Cited by 365
Modulation of Ras and a-Factor Function by Carboxyl-Terminal Proteolysis
Boyartchuk, V. L., Ashby, M. N., & Rine, J. (1997) · Science · doi:10.1126/science.275.5307.1796 · Cited by 361
Activation of RalA is critical for Ras-induced tumorigenesis of human cells
Lim, K.-H., Baines, A. T., Fiordalisi, J. J., Shipitsin, M., Feig, L. A., Cox, A. D., Der, C. J., & Counter, C. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.030 · Cited by 355
Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival
Drosten, M., Dhawahir, A., Sum, E. Y. M., Urosevic, J., Lechuga, C. G., Esteban, L. M., Castellano, E., Guerra, C., Santos, E., & Barbacid, M. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.7 · Cited by 347
Khosravi-Far, R., White, M. A., Westwick, J. K., Solski, P. A., Chrzanowska-Wodnicka, M., Van Aelst, L., Wigler, M. H., & Der, C. J. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.7.3923 · Cited by 343
The prevalence of PIK3CA mutations in gastric and colon cancer
Velho, S., Oliveira, C., Ferreira, A., Ferreira, A. C., Suriano, G., Schwartz, S., Duval, A., Carneiro, F., Machado, J. C., Hamelin, R., et al. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.04.022 · Cited by 341
Deshpande, N. (2004) · Nucleic Acids Research · doi:10.1093/nar/gki057 · Cited by 340
Urano, T., Emkey, R., & Feig, L. A. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00416.x · Cited by 331
Barault, L., Veyrie, N., Jooste, V., Lecorre, D., Chapusot, C., Ferraz, J., Lièvre, A., Cortet, M., Bouvier, A., Rat, P., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23388 · Cited by 331
Ruggeri, B. A., Huang, L., Wood, M., Cheng, J. Q., & Testa, J. R. (1998) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199802)21:2<81::aid-mc1>3.3.co;2-k · Cited by 329
Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism
Lambert, J. M., Lambert, Q. T., Reuther, G. W., Malliri, A., Siderovski, D. P., Sondek, J., Collard, J. G., & Der, C. J. (2002) · Nature Cell Biology · doi:10.1038/ncb833 · Cited by 326
Regulation of a Novel Human Phospholipase C, PLCε, through Membrane Targeting by Ras
Song, C., Hu, C.-D., Masago, M., Kariya, K.-I., Yamawaki-Kataoka, Y., Shibatohge, M., Wu, D., Satoh, T., & Kataoka, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008324200 · Cited by 320
Liu, M., Bryant, M., Chen, J., Lee, S., Yaremko, B., Lipari, P., Malkowski, M. G., Ferrari, E., Nielsen, L. L., Prioli, N. A., et al. (1998) · PubMed · Cited by 309
Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?
Repasky, G. A., Chenette, E. J., & Der, C. J. (2004) · Trends in Cell Biology · doi:10.1016/j.tcb.2004.09.014 · Cited by 300
Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors
Basso, A. D., Kirschmeier, P., & Bishop, W. R. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r500012-jlr200 · Cited by 297
Induction of cyclin D1 overexpression by activated ras.
Filmus, J., Robles, A. I., Shi, W., Wong, M. J. H., Colombo, L. L., & Conti, C. J. (1994) · PubMed · Cited by 295
Depalmitoylated Ras traffics to and from the Golgi complex via a nonvesicular pathway
Goodwin, J. S., Drake, K. R., Rogers, C., Wright, L., Lippincott-Schwartz, J., Philips, M. R., & Kenworthy, A. K. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200502063 · Cited by 294
The Role of Statins in Cancer Therapy
Hindler, K., Cleeland, C. S., Rivera, E., & Collard, C. D. (2006) · The Oncologist · doi:10.1634/theoncologist.11-3-306 · Cited by 291
Activated Ras interacts with the Ral guanine nucleotide dissociation stimulator.
Hofer, F., Fields, S., Schneider, C., & Martin, G. S. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.23.11089 · Cited by 287
New insight into BRAF mutations in cancer
Dhomen, N., & Marais, R. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.12.005 · Cited by 278
Ihle, N. T., Lemos, R., Wipf, P., Yacoub, A., Mitchell, C., Siwak, D., Mills, G. B., Dent, P., Kirkpatrick, D. L., & Powis, G. (2009) · Cancer Research · doi:10.1158/0008-5472.can-07-6656 · Cited by 274
The GTP binding motif: variations on a theme
Kjeldgaard, M., Nyborg, J., & Clark, B. F. C. (1996) · The FASEB Journal · doi:10.1096/fasebj.10.12.8903506 · Cited by 266
Spaargaren, M., & Bischoff, J. R. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.26.12609 · Cited by 265
ralGDS family members interact with the effector loop of ras p21.
Kikuchi, A., Demo, S. D., Ye, Z. H., Chen, Y. W., & Williams, L. T. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.11.7483 · Cited by 259
Sos, M. L., Fischer, S., Ullrich, R., Peifer, M., Heuckmann, J. M., Koker, M., Heynck, S., Stückrath, I., Weiss, J., Fischer, F., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907325106 · Cited by 254
From basic research to clinical development of MEK1/2 inhibitors for cancer therapy
Frémin, C., & Meloche, S. (2010) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-3-8 · Cited by 243
White, M. A., Vale, T., Camonis, J. H., Schaefer, E., & Wigler, M. H. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.28.16439 · Cited by 240
Lobell, R. B., Omer, C. A., Abrams, M. T., Bhimnathwala, H., Brucker, M. J., Buser, C. A., Davide, J. P., DeSolms, S. J., Dinsmore, C. J., Ellis-Hutchings, M., et al. (2001) · PubMed · Cited by 239
Ral GTPases and cancer: linchpin support of the tumorigenic platform
Bodemann, B. O., & White, M. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2296 · Cited by 235
Ras plasma membrane signalling platforms
HANCOCK, J. F., & PARTON, R. G. (2005) · Biochemical Journal · doi:10.1042/bj20050231 · Cited by 232
Lenzen, C., Cool, R. H., Prinz, H., Kuhlmann, J., & Wittinghofer, A. (1998) · Biochemistry · doi:10.1021/bi972621j · Cited by 226
The Kinetic Mechanism of Ran-Nucleotide Exchange Catalyzed by RCC1
Klebe, C., Prinz, H., Wittinghofer, A., & Goody, R. S. (1995) · Biochemistry · doi:10.1021/bi00039a008 · Cited by 222
Robles, A. I., Rodriguez-Puebla, M. L., Glick, A. B., Trempus, C., Hansen, L., Sicinski, P., Tennant, R. W., Weinberg, R. A., Yuspa, S. H., & Conti, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.16.2469 · Cited by 217
Mapping the Nucleotide and Isoform-Dependent Structural and Dynamical Features of Ras Proteins
Gorfe, A. A., Grant, B. J., & McCammon, J. A. (2008) · Structure · doi:10.1016/j.str.2008.03.009 · Cited by 216
Carboxyl Methylation of Ras-Related Proteins During Signal Transduction in Neutrophils
Philips, M. R., Pillinger, M. H., Staud, R., Volker, C., Rosenfeld, M. G., Weissmann, G., & Stock, J. B. (1993) · Science · doi:10.1126/science.8438158 · Cited by 214
Gorfe, A. A., Hanzal-Bayer, M., Abankwa, D., Hancock, J. F., & McCammon, J. A. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061053f · Cited by 209
Crucial Role of Phospholipase Cε in Chemical Carcinogen-Induced Skin Tumor Development
Bai, Y., Edamatsu, H., Maeda, S., Saito, H., Suzuki, N., Satoh, T., & Kataoka, T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-3143 · Cited by 206
CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis
Lazarov, M., Kubo, Y., Cai, T., Dajee, M., Tarutani, M., Lin, Q., Fang, M., Tao, S., Green, C. L., & Khavari, P. A. (2002) · Nature Medicine · doi:10.1038/nm779 · Cited by 203
Regulation of Tiam1–Rac signalling
Mertens, A. E., Roovers, R. C., & Collard, J. G. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00435-6 · Cited by 196
RAL GTPases are linchpin modulators of human tumour‐cell proliferation and survival
Chien, Y., & White, M. A. (2003) · EMBO reports · doi:10.1038/sj.embor.embor899 · Cited by 193
Requirement of the NF-κB Subunit p65/RelA for K-Ras–Induced Lung Tumorigenesis
Bassères, D. S., Ebbs, A., Levantini, E., & Baldwin, A. S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4290 · Cited by 189
Westwick, J. K., Cox, A. D., Der, C. J., Cobb, M. H., Hibi, M., Karin, M., & Brenner, D. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.13.6030 · Cited by 187
Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response
Pratilas, C. A., & Solit, D. B. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3064 · Cited by 183
RalGDS is required for tumor formation in a model of skin carcinogenesis
González-García, A., Pritchard, C. A., Paterson, H. F., Mavria, G., Stamp, G., & Marshall, C. J. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.029 · Cited by 181
Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf
Bergo, M. O., Gavino, B. J., Hong, C., Beigneux, A. P., McMahon, M., Casey, P. J., & Young, S. G. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200418829 · Cited by 180
Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf
Bergö, M. O., Gavino, B. J., Hong, C., Beigneux, A. P., McMahon, M., Casey, P. J., & Young, S. G. (2004) · Journal of Clinical Investigation · doi:10.1172/jci18829 · Cited by 180
Role of Rho-family proteins in cell adhesion and cancer
Malliri, A., & Collard, J. G. (2003) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(03)00098-x · Cited by 172
Yoshida, T., Hisamoto, T., Akiba, J., Koga, H., Nakamura, K., Tokunaga, Y., Hanada, S., Kumemura, H., Maeyama, M., Harada, M., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209635 · Cited by 169
Halilovic, E., She, Q.-B., Ye, Q., Pagliarini, R., Sellers, W. R., Solit, D. B., & Rosen, N. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0409 · Cited by 168
Requirement for Rac1 in a K-ras–Induced Lung Cancer in the Mouse
Kissil, J. L., Walmsley, M. J., Hanlon, L., Haigis, K. M., Bender Kim, C. F., Sweet-Cordero, A., Eckman, M. S., Tuveson, D. A., Capobianco, A. J., Tybulewicz, V. L. J., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2300 · Cited by 167
Isoprenylcysteine Carboxyl Methyltransferase Deficiency in Mice
Bergo, M. O., Leung, G. K., Ambroziak, P., Otto, J. C., Casey, P. J., Gomes, A. Q., Seabra, M. C., & Young, S. G. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c000831200 · Cited by 162
Schaap, D., van der Wal, J., Howe, L. R., Marshall, C. J., & van Blitterswijk, W. J. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)80719-4 · Cited by 160
Yu, C. F., Liu, Z., & Cantley, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200732200 · Cited by 156
Fong, C. W., Chua, M., McKie, A. B., Ling, S. H. M., Mason, V., Li, R., Yusoff, P., Lo, T. L., Leung, H. Y., So, S. K., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1072 · Cited by 150
Three Separable Domains Regulate GTP-Dependent Association of H-ras with the Plasma Membrane
Rotblat, B., Prior, I. A., Muncke, C., Parton, R. G., Kloog, Y., Henis, Y. I., & Hancock, J. F. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.15.6799-6810.2004 · Cited by 150
Phospholipase C epsilon: linking second messengers and small GTPases
Bunney, T. D., & Katan, M. (2006) · Trends in Cell Biology · doi:10.1016/j.tcb.2006.10.007 · Cited by 148
Winter-Vann, A. M., Kamen, B. A., Bergö, M. O., Young, S. G., Melnyk, S., James, S. J., & Casey, P. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1135239100 · Cited by 146
Guanosine triphosphatase stimulation of oncogenic Ras mutants
Ahmadian, M. R., Zor, T., Vogt, D., Kabsch, W., Selinger, Z., Wittinghofer, A., & Scheffzek, K. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.7065 · Cited by 144
Absence of the CAAX Endoprotease Rce1: Effects on Cell Growth and Transformation
Bergö, M. O., Ambroziak, P., Gregory, C., George, A. M., Otto, J. C., Kim, E. J.-H., Nagase, H., Casey, P. J., Balmain, A., & Young, S. G. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.1.171-181.2002 · Cited by 142
Emerging anti-cancer molecular mechanisms of aminobisphosphonates
Caraglia, M., Santini, D., Marra, M., Vincenzi, B., Tonini, G., & Budillon, A. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01094 · Cited by 140
Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models
Vicent, S., Ron, C., Sayles, L. C., Lin, C., Walker, R. G., Gillespie, A. K., Subramanian, A., Hinkle, G., Yang, X., Saif, S., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci44165 · Cited by 138
Lackner, M. R., Kindt, R. M., Carroll, P. M., Brown, K. A., Cancilla, M. R., Chen, C., de Silva, H., Franke, Y., Guan, B., Heuer, T., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.024 · Cited by 136
Torbett, N. E., Luna-Moran, A., Knight, Z. A., Houk, A. R., Moasser, M. M., Weiss, W. A., Shokat, K. M., & Stokoe, D. (2008) · Biochemical Journal · doi:10.1042/bj20080639 · Cited by 134
Dan, S., Okamura, M., Seki, M., Yamazaki, K., Sugita, H., Okui, M., Mukai, Y., Nishimura, H., Asaka, R., Nomura, K., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4172 · Cited by 128
Identification of PLC210, a Caenorhabditis elegansPhospholipase C, as a Putative Effector of Ras
Shibatohge, M., Kariya, K., Liao, Y., Hu, C., Watari, Y., Goshima, M., Shima, F., & Kataoka, T. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.11.6218 · Cited by 127
Taveras, A. G., Remiszewski, S., Doll, R. J., Cesarz, D., Huang, E. C., Kirschmeier, P. T., Pramanik, B. N., Snow, M. E., Wang, Y.-S., del Rosario, J., et al. (1997) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(96)00202-7 · Cited by 123
Lobell, R. B., Liu, D., Buser, C. A., Davide, J. P., DePuy, E., Hamilton, K., Koblan, K. S., Lee, Y., Mosser, S. D., Motzel, S. L., et al. (2002) · PubMed · Cited by 121
Oncogenic signaling of class I PI3K isoforms
Denley, A., Kang, S. G., Kärst, U., & Vogt, P. K. (2007) · Oncogene · doi:10.1038/sj.onc.1210918 · Cited by 114
Wang, Z., Pedersen, E., Basse, A. L., Lefever, T., Peyrollier, K., Kapoor, S., Mei, Q., Karlsson, R. T. G., Chrostek‐Grashoff, A., & Brakebusch, C. (2010) · Oncogene · doi:10.1038/onc.2010.95 · Cited by 113
Wang, Y., Ngo, V. N., Marani, M., Yang, Y., Wright, G. W., Staudt, L. M., & Downward, J. (2010) · Oncogene · doi:10.1038/onc.2010.218 · Cited by 112
Binding of prenylated and polybasic peptides to membranes: affinities and intervesicle exchange
Ghomashchi, F., Zhang, X., Liu, L., & Gelb, M. H. (1995) · Biochemistry · doi:10.1021/bi00037a032 · Cited by 112
Tabancay, A. P., Gau, C., Machado, I. M. P., Uhlmann, E. J., Gutmann, D. H., Guo, L., & Tamanoi, F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306553200 · Cited by 110
Ashar, H. R., James, L. J., Gray, K., Carr, D. M., McGuirk, M., Maxwell, E., Black, S., Armstrong, L., Doll, R. J., Taveras, A. G., et al. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5076 · Cited by 109
Cyclin-Dependent Kinase 4 Expression Is Essential for Neu-Induced Breast Tumorigenesis
Reddy, H. K. D. L., Mettus, R. V., Rane, S. G., Graña, X., Litvin, J., & Reddy, E. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2639 · Cited by 108
Raf-1 Addiction in Ras-Induced Skin Carcinogenesis
Ehrenreiter, K., Kern, F., Velamoor, V., Meissl, K., Galabova‐Kovacs, G., Sibilia, M. C., & Baccarini, M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.008 · Cited by 106
Clinical and molecular aspects of RAS related disorders
Denayer, E., de Ravel, T. J. L., & Legius, E. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2007.055772 · Cited by 97
Njoroge, F. G., Taveras, A. G., Kelly, J. M., et al. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm980462b · Cited by 95
Inactivating Icmt ameliorates K-RAS–induced myeloproliferative disease
Wahlstrom, A. M., Cutts, B. A., Liu, M., Lindskog, A., Karlsson, C., Sjogren, A.-K. M., Andersson, K., Young, S. G., & Bergö, M. O. (2008) · Blood · doi:10.1182/blood-2007-06-094060 · Cited by 93
Fiordalisi, J. J., Johnson, R. L., Weinbaum, C., Sakabe, K., Chen, Z., Casey, P. J., & Cox, A. D. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305733200 · Cited by 90
Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation
Mishra, P. J., Ha, L., Rieker, J., Sviderskaya, E. V., Bennett, D. C., Oberst, M. D., Kelly, K., & Merlino, G. T. (2010) · Oncogene · doi:10.1038/onc.2009.521 · Cited by 76
Wang, M., Hossain, M. S., Tan, W., Coolman, B., Zhou, J., Liu, S., & Casey, P. J. (2010) · Oncogene · doi:10.1038/onc.2010.247 · Cited by 75
Rce1 deficiency accelerates the development of K-RAS–induced myeloproliferative disease
Wahlstrom, A. M., Cutts, B. A., Karlsson, C., Andersson, K., Liu, M., Sjogren, A.-K. M., Swolin, B., Young, S. G., & Bergö, M. O. (2006) · Blood · doi:10.1182/blood-2006-05-024752 · Cited by 73
Marr, R. S., Blair, L. C., & Thorner, J. W. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)30464-7 · Cited by 67
On the Physiological Importance of Endoproteolysis of CAAX Proteins
Bergö, M. O., Lieu, H. D., Gavino, B. J., Ambroziak, P., Otto, J. C., Casey, P. J., Walker, Q. M., & Young, S. G. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310081200 · Cited by 67
Antibodies specific for amino acid 12 of the ras oncogene product inhibit GTP binding.
Clark, R., Wong, G., Arnheim, N., Nitecki, D. E., & McCormick, F. P. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.16.5280 · Cited by 64
Self-citationSmall-Molecule Inhibitors of the Rce1p CaaX Protease
Manandhar, S. P., Hildebrandt, E. R., & Schmidt, W. K. (2007) · SLAS DISCOVERY · doi:10.1177/1087057107307226 · Cited by 64
Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma
Ollikainen, M., Gylling, A., Puputti, M., Nupponen, N. N., Abdel‐Rahman, W. M., Bützow, R. C., & Peltomäki, P. (2007) · International Journal of Cancer · doi:10.1002/ijc.22768 · Cited by 62
Smakman, N., Veenendaal, L. M., van Diest, P. J., Bos, R., Offringa, R., Rinkes, I. H. M. B., & Kranenburg, O. (2005) · Oncogene · doi:10.1038/sj.onc.1208995 · Cited by 51
Ral activation promotes melanomagenesis
Zipfel, P. A., Brady, D. C., Kashatus, D. F., Ancrile, B. D., Tyler, D. S., & Counter, C. M. (2010) · Oncogene · doi:10.1038/onc.2010.224 · Cited by 47
The Raf Inhibitor Paradox: Unexpected Consequences of Targeted Drugs
Cox, A. D., & Der, C. J. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.02.029 · Cited by 42
Inhibition of the CaaX proteases Rce1p and Ste24p by peptidyl (acyloxy)methyl ketones
Porter, S. B., Hildebrandt, E. R., Breevoort, S. R., Mokry, D. Z., Dore, T. M., & Schmidt, W. K. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2007.03.004 · Cited by 37
H-ras and raf-1 cooperate in transformation of NIH3T3 fibroblasts.
Cuadrado, A., Bruder, J. T., Heidaran, M. A., App, H., Rapp, U. R., & Aaronson, S. A. (1993) · PubMed · Cited by 36
Cooperativity ofCdk4R24CandRasin melanoma development
Chawla, R., Procknow, J. A., Tantravahi, R. V., Khurana, J., Litvin, J., & Reddy, E. P. (2010) · Cell Cycle · doi:10.4161/cc.9.16.12632 · Cited by 24
Genetic and Pharmacologic Dissection of Ras Effector Utilization in Oncogenesis
Campbell, P. M., Singh, A., Williams, F. J., Frantz, K., Ülkü, A. S., Kelley, G. G., & Der, C. J. (2006) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(05)07017-5 · Cited by 23
How Ras works: structure of a Rap–Raf complex
Sprang, S. R. (1995) · Structure · doi:10.1016/s0969-2126(01)00198-8 · Cited by 19
Ral Is both Necessary and Sufficient for the Inhibition of Myeloid Differentiation Mediated by Ras
Omidvar, N., Pearn, L., Burnett, A. K., & Darley, R. L. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.10.3966-3975.2006 · Cited by 19
Reddy, H. K. D. L., Graña, X., Dhanasekaran, D. N., Litvin, J., & Reddy, E. P. (2010) · Genes & Cancer · doi:10.1177/1947601909358105 · Cited by 18
Hollander, I. J., Frommer, E., AULABAUGH, A. E., & Mallon, R. G. (2003) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/s1570-9639(03)00150-x · Cited by 13
Using cells devoid of RAS proteins as tools for drug discovery
Urosevic, J., Sum, E. Y. M., Moneo, V., Drosten, M., Dhawahir, A., Becerra, M., Carnero, A., & Barbacid, M. (2009) · Molecular Carcinogenesis · doi:10.1002/mc.20555 · Cited by 9
Cited by
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
Kamerkar, S., LeBleu, V. S., Sugimoto, H., Yang, S., Ruivo, C. F., Melo, S. A., Lee, J. J., & Kalluri, R. (2017) · Nature · doi:10.1038/nature22341 · Cited by 2,639
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
Bahar, M. E., Kim, H. J., & Kim, D. R. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01705-z · Cited by 888
Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795
Self-citationBiochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
Hunter, J. C., Manandhar, A., Carrasco, M. A., Gurbani, D., Gondi, S., & Westover, K. D. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0203 · Cited by 786
“GAP-stimulated KRAS-mutant GTPase activity Mutations in codons 12 and 13 dampen RAS responses to GAPs, such as P120GAP and NF1, resulting in slower rates of stimulatedGTP hydrolysis (27, 52).”
Background
Metadata
- Authors
- Gysin, S., Salt, M., Young, A., & McCormick, F.
- Venue
- Genes & Cancer
- Publisher
- SAGE Publications
- Published
- 2011-03-01
- Volume
- 2
- Issue
- 3
- Pages
- 359-372
- ISSN
- 1947-6019 (ISSN-L)
- 1947-6027
- OpenAlex
- W2109031404
- Cited by
- 323
- References
- 173
- FWCI
- 9.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.